tiprankstipranks
Trending News
More News >
Abbott Laboratories (ABT)
NYSE:ABT
US Market
Advertisement

Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare
8,718 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
20Ratings
Strong Buy
17 Buy
3 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$146.06
▲(9.37% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $146.06 with a high forecast of $159.00 and a low forecast of $135.00. The average price target represents a 9.37% change from the last price of $133.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"110":"$110","135":"$135","160":"$160","122.5":"$122.5","147.5":"$147.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$159.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$146.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$135.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[110,122.5,135,147.5,160],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.46,133.57846153846154,135.69692307692307,137.81538461538463,139.93384615384616,142.0523076923077,144.17076923076922,146.28923076923078,148.40769230769232,150.52615384615385,152.64461538461538,154.76307692307694,156.88153846153847,{"y":159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.46,132.58307692307693,133.70615384615385,134.82923076923078,135.9523076923077,137.07538461538462,138.19846153846154,139.32153846153847,140.4446153846154,141.5676923076923,142.69076923076923,143.81384615384616,144.93692307692308,{"y":146.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.46,131.7323076923077,132.0046153846154,132.27692307692308,132.54923076923077,132.82153846153847,133.09384615384616,133.36615384615385,133.63846153846154,133.91076923076923,134.18307692307692,134.45538461538462,134.7276923076923,{"y":135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":111.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$159.00Average Price Target$146.06Lowest Price Target$135.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$148$154
Buy
15.31%
Upside
Reiterated
09/23/25
UBS Remains a Buy on Abbott Laboratories (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $154.00 price target on Abbott Labs (NYSE: ABT).
TR | OpenAI - 4o Analyst forecast on ABT
TR | OpenAI - 4o
TR | OpenAI - 4o
$147$152
Buy
13.82%
Upside
Reiterated
09/12/25
AI Generated ArticleAI Generated Article
Bernstein Analyst forecast on ABT
Bernstein
Bernstein
$145
Buy
8.57%
Upside
Reiterated
09/08/25
Bernstein Remains a Buy on Abbott Laboratories (ABT)We rate ABT, BSX, DXCM, ISRG, MDT, SYK, and PODD Outperform.
Piper Sandler Analyst forecast on ABT
Piper Sandler
Piper Sandler
$150
Buy
12.32%
Upside
Reiterated
09/05/25
Piper Sandler Remains a Buy on Abbott Laboratories (ABT)
Leerink Partners Analyst forecast on ABT
Leerink Partners
Leerink Partners
Hold
Reiterated
08/29/25
We expect Navitor's CE Mark, expanding the label to low- and intermediate-risk patients with severe AS, to represent a modest incremental positive for ABT (MP). This expanded label could help level the OUS playing field with both EW (MP) and MDT (OP) who previously received CE Mark across all risk categories. As a reminder, EW's SAPIEN 3 received CE Mark in intermediate risk patients in 2016, low risk patients in 2019, and remains the only TAVR valve indicated for asymptomatic severe patients in Europe. FX+ received CE Mark for all risk categories in 2024. Considering the BSX (OP) OUS share newly up-for-grabs following ACURATE's recent discontinuation, we believe the additional eligibility resulting from this label expansion could represent a modest incremental growth driver for ABT's OUS TAVR franchise.
Citi
$155
Buy
16.06%
Upside
Reiterated
08/27/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe rate ABT and MDT Buy, and EW Buy/Top Pick with a Positive Catalyst Watch.
Jefferies
Buy
Reiterated
08/18/25
We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.
Wells Fargo Analyst forecast on ABT
Wells Fargo
Wells Fargo
$151$142
Buy
6.33%
Upside
Reiterated
07/21/25
Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)
Raymond James Analyst forecast on ABT
Raymond James
Raymond James
$142$141
Buy
5.58%
Upside
Reiterated
07/18/25
Abbott price target lowered to $141 from $142 at Raymond JamesAbbott price target lowered to $141 from $142 at Raymond James
Oppenheimer Analyst forecast on ABT
Oppenheimer
Oppenheimer
$140
Buy
4.83%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Abbott Laboratories (NYSE: ABT) and ANI Pharmaceuticals (NASDAQ: ANIP)
Barclays Analyst forecast on ABT
Barclays
Barclays
$159
Buy
19.06%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Tarsus Pharmaceuticals (NASDAQ: TARS) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on ABT
Bank of America Securities
Bank of America Securities
$150
Buy
12.32%
Upside
Reiterated
07/18/25
Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction
Mizuho Securities Analyst forecast on ABT
Mizuho Securities
Mizuho Securities
$140$135
Hold
1.09%
Upside
Reiterated
07/18/25
Mizuho Securities Remains a Hold on Abbott Laboratories (ABT)
Stifel Nicolaus Analyst forecast on ABT
Stifel Nicolaus
Stifel Nicolaus
$145
Buy
8.57%
Upside
Reiterated
07/18/25
Stifel Nicolaus Keeps Their Buy Rating on Abbott Laboratories (ABT)
TD Cowen
$145
Buy
8.57%
Upside
Reiterated
07/17/25
Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$148$154
Buy
15.31%
Upside
Reiterated
09/23/25
UBS Remains a Buy on Abbott Laboratories (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $154.00 price target on Abbott Labs (NYSE: ABT).
TR | OpenAI - 4o Analyst forecast on ABT
TR | OpenAI - 4o
TR | OpenAI - 4o
$147$152
Buy
13.82%
Upside
Reiterated
09/12/25
AI Generated ArticleAI Generated Article
Bernstein Analyst forecast on ABT
Bernstein
Bernstein
$145
Buy
8.57%
Upside
Reiterated
09/08/25
Bernstein Remains a Buy on Abbott Laboratories (ABT)We rate ABT, BSX, DXCM, ISRG, MDT, SYK, and PODD Outperform.
Piper Sandler Analyst forecast on ABT
Piper Sandler
Piper Sandler
$150
Buy
12.32%
Upside
Reiterated
09/05/25
Piper Sandler Remains a Buy on Abbott Laboratories (ABT)
Leerink Partners Analyst forecast on ABT
Leerink Partners
Leerink Partners
Hold
Reiterated
08/29/25
We expect Navitor's CE Mark, expanding the label to low- and intermediate-risk patients with severe AS, to represent a modest incremental positive for ABT (MP). This expanded label could help level the OUS playing field with both EW (MP) and MDT (OP) who previously received CE Mark across all risk categories. As a reminder, EW's SAPIEN 3 received CE Mark in intermediate risk patients in 2016, low risk patients in 2019, and remains the only TAVR valve indicated for asymptomatic severe patients in Europe. FX+ received CE Mark for all risk categories in 2024. Considering the BSX (OP) OUS share newly up-for-grabs following ACURATE's recent discontinuation, we believe the additional eligibility resulting from this label expansion could represent a modest incremental growth driver for ABT's OUS TAVR franchise.
Citi
$155
Buy
16.06%
Upside
Reiterated
08/27/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe rate ABT and MDT Buy, and EW Buy/Top Pick with a Positive Catalyst Watch.
Jefferies
Buy
Reiterated
08/18/25
We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.
Wells Fargo Analyst forecast on ABT
Wells Fargo
Wells Fargo
$151$142
Buy
6.33%
Upside
Reiterated
07/21/25
Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)
Raymond James Analyst forecast on ABT
Raymond James
Raymond James
$142$141
Buy
5.58%
Upside
Reiterated
07/18/25
Abbott price target lowered to $141 from $142 at Raymond JamesAbbott price target lowered to $141 from $142 at Raymond James
Oppenheimer Analyst forecast on ABT
Oppenheimer
Oppenheimer
$140
Buy
4.83%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Abbott Laboratories (NYSE: ABT) and ANI Pharmaceuticals (NASDAQ: ANIP)
Barclays Analyst forecast on ABT
Barclays
Barclays
$159
Buy
19.06%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Tarsus Pharmaceuticals (NASDAQ: TARS) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on ABT
Bank of America Securities
Bank of America Securities
$150
Buy
12.32%
Upside
Reiterated
07/18/25
Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction
Mizuho Securities Analyst forecast on ABT
Mizuho Securities
Mizuho Securities
$140$135
Hold
1.09%
Upside
Reiterated
07/18/25
Mizuho Securities Remains a Hold on Abbott Laboratories (ABT)
Stifel Nicolaus Analyst forecast on ABT
Stifel Nicolaus
Stifel Nicolaus
$145
Buy
8.57%
Upside
Reiterated
07/18/25
Stifel Nicolaus Keeps Their Buy Rating on Abbott Laboratories (ABT)
TD Cowen
$145
Buy
8.57%
Upside
Reiterated
07/17/25
Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month
xxx
Success Rate
20/28 ratings generated profit
71%
Average Return
+1.16%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.16% per trade.
3 Months
xxx
Success Rate
23/28 ratings generated profit
82%
Average Return
+5.27%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 82.14% of your transactions generating a profit, with an average return of +5.27% per trade.
1 Year
Rick WiseStifel Nicolaus
Success Rate
23/24 ratings generated profit
96%
Average Return
+15.88%
reiterated a buy rating 2 months ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 95.83% of your transactions generating a profit, with an average return of +15.88% per trade.
2 Years
xxx
Success Rate
24/28 ratings generated profit
86%
Average Return
+17.67%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +17.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
49
42
45
41
39
Hold
3
4
4
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
52
46
49
46
43
In the current month, ABT has received 39 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 146.06.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.30 with a range of $1.28 to $1.37. The previous quarter’s EPS was $1.26. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.
Next quarter’s earnings estimate for ABT is $1.30 with a range of $1.28 to $1.37. The previous quarter’s EPS was $1.26. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.40B with a range of $11.22B to $11.50B. The previous quarter’s sales results were $11.14B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.
Next quarter’s sales forecast for ABT is $11.40B with a range of $11.22B to $11.50B. The previous quarter’s sales results were $11.14B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 146.06.
    What is ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 9.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABT a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s price target?
            The average price target for Abbott Laboratories is 146.06. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $159.00 ,the lowest forecast is $135.00. The average price target represents 9.37% Increase from the current price of $133.55.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of ABT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis